BFM
IRD

Boothbay Fund Management’s Opus Genetics IRD Stock Holding History

Boothbay Fund Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.89M Buy
1,189,515
+402
+0% +$1.88K 0.06% 365
2026
Q1 		$5.41M Buy
+1,189,113
New +$4.11M 0.07% 300
2022
Q2 		– Sell
-11,901
Closed -$39K – 2737
2022
Q1 		$39K Hold
11,901
– – ﹤0.01% 2201
2021
Q4 		$44K Hold
11,901
– – ﹤0.01% 1779
2021
Q3 		$61K Sell
11,901
-1,488
-11% -$6.86K ﹤0.01% 1833
2021
Q2 		$71K Hold
13,389
– – ﹤0.01% 1761
2021
Q1 		$78K Buy
+13,389
New +$124K ﹤0.01% 1485

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boothbay Fund Management's IRD Position: Q2 2026 in Review

Boothbay Fund Management increased its Opus Genetics (IRD) stake by 0.03% in Q2 2026, buying an estimated $1.88K and bringing the position to 1,189,515 shares worth $4.89M. The position accounts for 0.06% of the portfolio, ranked #365.

Boothbay Fund Management first reported a position in IRD in Q1 2021 and has held it in 7 quarters since. The position peaked at $5.41M in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Boothbay Fund Management held 1,189,515 shares of Opus Genetics worth $4.89M as of Q2 2026.
  • Boothbay Fund Management bought 402 Opus Genetics shares in Q2 2026, an estimated $1.88K.
  • Opus Genetics made up 0.06% of Boothbay Fund Management's portfolio in Q2 2026, its #365 holding.
  • Boothbay Fund Management first reported a position in Opus Genetics in Q1 2021 and has held it in 7 quarters since.
  • Boothbay Fund Management's Opus Genetics position peaked at $5.41M in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.